Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
The RANZCP Board has approved a change to membership criteria under which specialist international m...
RANZCP trainees or Fellows who are passionate about training or practising psychiatry in a rural loc...
14 November 2025
Leading psychiatrists from across Aotearoa New Zealand and Australia have joined senior public healt...